Nautilus Biotechnology, Inc. · NASDAQ:NAUT
Marc L. Andreessen reported a 9.90% stake in Nautilus Biotechnology, Inc. (Schedule 13D/A)
Event Jun 2, 2026 · Filed Jun 4, 2026
Marc L. Andreessen reported a 9.90% stake in Nautilus Biotechnology, Inc., 12,653,917 shares, with active intent on Jun 2, 2026. Filed Jun 4, 2026 (Schedule 13D/A).
- Stake
- 9.90%
- Shares
- 12,653,917
- Intent
- Active
- What changed
- Stake changed
- Filed together
- 6 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| AH Bio Fund II, L.P. | 9.20% | 11,682,032 |
| AH Equity Partners Bio II, L.L.C. | 9.20% | 11,682,032 |
| Andreessen Horowitz LSV Fund II, L.P. | 0.80% | 971,885 |
| AH Equity Partners LSV II, L.L.C. | 0.80% | 971,885 |
| Marc L. Andreessen | 9.90% | 12,653,917 |
| Benjamin A. Horowitz | 9.90% | 12,653,917 |
Source
Related
- Nautilus Biotechnology, Inc.
- Andreessen Marc L
- Nautilus Biotechnology, Inc. shareholders
- Schedule 13D/A · Andreessen Marc L · Sep 11, 2026
- Schedule 13D/A · Andreessen Marc L · Aug 28, 2026
- Schedule 13D/A · Andreessen Marc L · Jun 30, 2026
- Schedule 13D/A · Perceptive Advisors LLC · Aug 14, 2026
- Form 4 · AH Bio Fund II, L.P. · Jun 4, 2026
- Schedule 13D/A · Sujal Patel · Mar 4, 2026
- Schedule 13D/A · Parag Mallick · Mar 4, 2026
- Schedule 13D/A · Perceptive Advisors LLC · Jun 24, 2025